The Response to Second-line Induction with Bortezomib and Dexamethasone is Predictive of Long-term Outcomes Prior to High-dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma-Reference-Cited by-同舟云学术

The Response to Second-line Induction with Bortezomib and Dexamethasone is Predictive of Long-term Outcomes Prior to High-dose Chemotherapy with Autologous Stem Cell Transplantation for Multiple Myeloma

Published:2013 Issue:9 Volume:52 Page:961-968
ISSN:0918-2918
Container-title:Internal Medicine
language:en
Short-container-title:Intern. Med.

Author:

Kobayashi Tsutomu¹,Kuroda Junya¹,Fuchida Shin-ichi²,Murakami Satoshi²,Hatsuse Mayumi²,Okano Akira²,Iwai Toshiki³,Tsutsumi Yasuhiko³,Kamitsuji Yuri⁴,Akaogi Teruaki⁵,Kawata-Iida Eri⁵,Shimizu Daisuke⁵,Uchiyama Hitoji¹,Matsumoto Yosuke¹,Horiike Shigeo¹,Nakao Mitsushige⁶,Takahashi Ryoichi⁷,Kaneko Hiroto³,Uoshima Nobuhiko⁴,Kobayashi Yutaka⁵,Shimazaki Chihiro²,Taniwaki Masafumi¹

Affiliation:

1. Division of Hematology and Oncology, Department of Medicine, Kyoto Prefectural University of Medicine, Japan

2. Department of Hematology, Kyoto Social Insurance Hospital, Japan

3. Department of Hematology, Kyoto First Red Cross Hospital, Japan

4. Department of Hematology, Matsushita Memorial Hospital, Japan

5. Department of Hematology, Kyoto Second Red Cross Hospital, Japan

6. Department of Medicine, Otsu Municipal Hospital, Japan

7. Department of Hematology, Ohmi-Hachiman Community Medical Center, Japan

Publisher

Japanese Society of Internal Medicine

Subject

General Medicine,Internal Medicine

Link

https://www.jstage.jst.go.jp/article/internalmedicine/52/9/52_52.9385/_pdf

Reference31 articles.

1. 1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Français du Myélome. New Engl J Med 335: 91-97, 1996.

2. 2. Attal M, Harousseau JL, Facon T, et al; InterGroupe Francophone du Myélome. Single versus double autologous stem-cell transplantation for multiple myeloma. New Engl J Med 349: 2495-2502, 2003.

3. 3. van de Velde HJ, Liu X, Chen G, Cakana A, Deraedt W, Bayssas M. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma. Haematologica 92: 1399-1406, 2007.

4. 4. Lahuerta JJ, Mateos MV, Martínez-López J, et al. Influence of pre- and post-transplantation responses on outcome of patients with multiple myeloma: sequential improvement of response and achievement of complete response are associated with longer survival. J Clin Oncol 26: 5775-5782, 2008.

5. 5. Chanan-Khan AA, Giralt S. Importance of achieving a complete response in multiple myeloma, and the impact of novel agents. J Clin Oncol 28: 2612-2624, 2010.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Management of induction failures in newly diagnosed transplant-eligible multiple myeloma;Leukemia & Lymphoma;2019-09-10

2. Phase II study of bortezomib, cyclophosphamide and dexamethasone as induction therapy in multiple myeloma: DSMM XI trial;British Journal of Haematology;2017-09-29

3. Treatment options for relapse after autograft in multiple myeloma – report from an EBMT educational meeting;Leukemia & Lymphoma;2016-09-21

4. Early response-based intensification of primary therapy in newly diagnosed multiple myeloma patients who are eligible for autologous stem cell transplantation: phase II study;Annals of Hematology;2014-04-12